Tactile Systems Raises Full-Year EBITDA Guidance Following Strong Lymphedema Growth
Tactile Systems (TCMD) reported strong third-quarter 2026 results, highlighted by a 13% year-over-year revenue increase in its core lymphedema segment to $81.8 million. Despite temporary inventory delays in the airway clearance business due to customers transitioning to the next-generation AffloVest system, the company raised its full-year adjusted EBITDA guidance to a range of $50 million to $52 million. The company is leveraging artificial intelligence and operational restructuring to improve efficiency, successfully reducing medical record review times by approximately 50%. Management remains optimistic about long-term growth, driven by expanding patient access in the lymphedema market and improved operating leverage through technological enhancements.
Tickers: $TCMD
Topics: AI Implementation EBITDA Guidance Lymphedema Treatment Revenue Growth